News
ICCM
1.190
+1.71%
0.020
Weekly Report: what happened at ICCM last week (0422-0426)?
Weekly Report · 3d ago
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
NASDAQ · 3d ago
Weekly Report: what happened at ICCM last week (0415-0419)?
Weekly Report · 04/22 12:09
IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA
NASDAQ · 04/18 15:07
BTTR, ICCM and SXTC among pre-market losers
Seeking Alpha · 04/17 12:21
HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
Benzinga · 04/16 15:03
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)
TipRanks · 04/16 10:30
IceCure Medical Announces Upcoming Shareholders Meeting
TipRanks · 04/16 01:02
IceCure Medical Eyes FDA Approval with Promising Trial Results
TipRanks · 04/16 00:58
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results; Data Submitted To FDA Requesting Marketing Authorization To Treat Early-Stage Breast Cancer
Data presentation at highly influential American Society of Breast Surgeons Annual Meeting by Dr. Richard Fine wins Scientific Impact Award. Company seeks indication for treating women with early stage T1 invasive breast cancer with adjuvant hormone therapy. ProSense® cryoablation offers highly favorable healthcare economics.
Benzinga · 04/15 12:37
ICECURE MEDICAL REPORTS FINAL ICE3 BREAST CANCER CRYOABLATION TRIAL RESULTS OF 100% PATIENT AND PHYSICIAN SATISFACTION AND 96.3% RECURRENCE FREE RATE: DATA SUBMITTED TO FDA REQUESTING MARKETING AUTHORIZATION TO TREAT EARLY-STAGE BREAST CANCER
Reuters · 04/15 12:35
Weekly Report: what happened at ICCM last week (0408-0412)?
Weekly Report · 04/15 11:59
Weekly Report: what happened at ICCM last week (0401-0405)?
Weekly Report · 04/08 12:06
Icecure Medical: Strong Buy on Impressive Q4 Revenue and Promising Regulatory Milestones
TipRanks · 04/05 11:25
HC Wainwright & Co. Reiterates Buy on Icecure Medical, Maintains $3 Price Target
Benzinga · 04/04 10:31
Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Icecure Medical (ICCM)
TipRanks · 04/04 10:31
Icecure Medical in Jeopardy: Navigating Nasdaq Delisting Risks and Future Uncertainties
TipRanks · 04/04 06:00
Icecure Medical Q4 EPS $(0.07), Inline, Sales $1.25M Beat $1.17M Estimate
Benzinga · 04/04 03:27
ICCM Stock Earnings: Icecure Medical Meets EPS, Beats Revenue for Q4 2023
Icecure Medical reported earnings per share of -7 cents for the fourth quarter of 2023. The company reported revenue of $1.26 million. This was 7.26% better than the analyst estimate for revenue of -6 cents. Icecure medical reported results for the quarter of 1923.
Investorplace · 04/03 16:52
IceCure Medical reports FY results
Seeking Alpha · 04/03 14:42
More
Webull provides a variety of real-time ICCM stock news. You can receive the latest news about Icecure Medical Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.